Repairon Co-Founder, Prof. Zimmermann, shares his thought in panel discussion at the Falling Walls Science Summit 2023 in Berlin (link to video).

BioVAT-HF Phase 1/2 reveals first evidence for effective heart repair in Advanced Heart Failure (Download pdf)

Repairon appoints Co-Founder Dr. Lothar Germeroth as Chief Executive Officer (Download pdf)

Repairon announces completion of dose-finding part of BioVAT-HF Phase 1/2 trial in Advanced Heart Failure (Download pdf)

BioVAT-HF: dose escalation completed with 9 patients treated – expected report of data in Q1/2023

Upscaling of cell production from T-flasks to stirred-tank Bioreactor

Upscaling of EHM patch from 1x (40x106 cells) to 10x EHM (400x106 cells)

2nd generation hypoimmune product for pre-clinical testing

(Statement after confirmation by DSMB in Q1)

First patient treated in BioVAT-HF study

Seed financing - 3rd round, including support from Sana Biotech

Experimental proof of concept for hypoimmune tissue approach

Own patent applications for process-related IP

Clinical Trial authorisation (CTA) for BioVAT-HF

GMP manufacturing authorization for IMP (investigational medicinal product)

Extension of core-IP license

Successfull validation of iPSC line for safety and function

Seed financing - 2nd round

GMP compliant manufacturing process established

Set-up of a GMP compliant iPSC working cell bank (WCB)

Acquisition of a GMP-grade iPSC line with commercial freedom to operate

Own patent applications for process-related IP

Licensing of IP for hypo-immune tissues (2nd generation products)

Licensing of additional IP to secure freedom to operate

Collaboration agreement with University of Göttingen Medical School (UMG)

Seed financing - 1st round

Appointment of Dr. Rainer Knaus as CEO

Licensing of core-IP

Company foundation